Trials / Conditions / Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

12 registered clinical trials studyying Relapsed/Refractory B-cell Malignancies — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignanc NCT07493174	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Recruiting	Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malign NCT07345728	Donghua Zhang	N/A
Recruiting	IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies NCT07309900	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 1
Recruiting	Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies NCT07240974	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	EARLY_Phase 1
Recruiting	The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies NCT07002112	The First Affiliated Hospital with Nanjing Medical University	Phase 1
Recruiting	UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies NCT06590961	Ubix Therapeutics, Inc.	Phase 1
Recruiting	A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034	Accutar Biotechnology Inc	Phase 1
Unknown	A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies NCT04861779	Haisco Pharmaceutical Group Co., Ltd.	Phase 1
Unknown	CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies NCT04943016	National Taiwan University Hospital	Phase 1
Unknown	This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies NCT04689308	Minghui Pharmaceutical (Shanghai) LTD	Phase 1
Unknown	Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy W NCT02825836	Telios Pharma, Inc.	Phase 1 / Phase 2
Completed	Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Ma NCT02457559	Gilead Sciences	Phase 1